Yu Cao, Fan Chong-Qi, Chen Yao-Xuan, Guo Feng, Rao Hao-Han, Che Peng-Yu, Zuo Chun-Jian, Chen Huan-Wen
Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, 400010, China.
Department of Cardiothoracic Surgery, Chongqing University Jiangjin Hospital, Chongqing, 402260, China.
Discov Oncol. 2025 Jan 11;16(1):33. doi: 10.1007/s12672-025-01782-2.
PURPOSE: Nano-drug delivery systems (NDDS) have become a promising alternative and adjunctive strategy for lung cancer (LC) treatment. However, comprehensive bibliometric analyses examining global research efforts on NDDS in LC are scarce. This study aims to fill this gap by identifying key research trends, emerging hotspots, and collaboration networks within the field of NDDS and LC. METHODS: A total of 2452 publications, spanning from 1998 to 2024, were extracted from the Web of Science Core Collection. The data were analyzed using tools such as VOSviewer, CiteSpace, and the R package 'bibliometrix'. RESULTS: The analysis covered contributions from 12,539 researchers affiliated with 2689 institutions across 55 countries, with their work published in 551 different journals. Research output has increased steadily, with China and the United States leading in both publication volume and impact. Major contributors include the Chinese Academy of Sciences and Shanghai Jiao Tong University. The International Journal of Nanomedicine published the most articles, while Journal of Controlled Release ranked highest in co-citations. Kamal Dua authored the most papers, and Maeda, H. was the most frequently co-cited author. Key research areas encompass "active targeting", "drug delivery optimization", "overcoming drug resistance", "nanocarriers", and "pulmonary drug delivery". Emerging hotspots include "epithelial mesenchymal transition", "mucus penetration", "lipid nanoparticles", "hydrogels", and "immune checkpoint inhibitors". CONCLUSION: This bibliometric analysis, the first comprehensive study on NDDS in LC, identifies China and the United States as leading contributors in publication volume and impact. Key research areas include "active targeting" and "drug delivery optimization", with emerging hotspots such as "lipid nanoparticles" and "immune checkpoint inhibitors". These findings provide essential insights to guide future research and optimize treatment strategies.
目的:纳米药物递送系统(NDDS)已成为肺癌(LC)治疗中一种有前景的替代和辅助策略。然而,对LC中NDDS的全球研究工作进行全面文献计量分析的研究很少。本研究旨在通过确定NDDS和LC领域内的关键研究趋势、新兴热点和合作网络来填补这一空白。 方法:从科学网核心合集中提取了1998年至2024年期间的2452篇出版物。使用VOSviewer、CiteSpace和R包“bibliometrix”等工具对数据进行了分析。 结果:该分析涵盖了来自55个国家2689个机构的12539名研究人员的贡献,他们的工作发表在551种不同的期刊上。研究产出稳步增长,中国和美国在发表量和影响力方面均领先。主要贡献者包括中国科学院和上海交通大学。《国际纳米医学杂志》发表的文章最多,而《控制释放杂志》在共被引方面排名最高。卡迈勒·杜阿撰写的论文最多,前田浩是被引频率最高的共同作者。关键研究领域包括“主动靶向”、“药物递送优化”、“克服耐药性”、“纳米载体”和“肺部药物递送”。新兴热点包括“上皮间质转化”、“黏液渗透”、“脂质纳米颗粒”、“水凝胶”和“免疫检查点抑制剂”。 结论:这项文献计量分析是对LC中NDDS的首次全面研究,确定中国和美国是发表量和影响力方面的主要贡献者。关键研究领域包括“主动靶向”和“药物递送优化”,新兴热点如“脂质纳米颗粒”和“免疫检查点抑制剂”。这些发现为指导未来研究和优化治疗策略提供了重要见解。
Heliyon. 2024-12-16
Front Immunol. 2023
Transl Lung Cancer Res. 2024-12-31
Front Pharmacol. 2023-9-14
Front Oncol. 2025-3-31
Signal Transduct Target Ther. 2024-9-16
Pharmaceuticals (Basel). 2024-8-12
Naunyn Schmiedebergs Arch Pharmacol. 2025-1
Front Pharmacol. 2024-7-25
Pharmaceuticals (Basel). 2024-5-24